PDSB News and Press, PDS Biotechnology Corporation From 07/26/21

FLORHAM PARK, N.J., July 26, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, will release financial re...

On the conclusion of the 2021 Russell indexes annual reconstitution, clinical-stage immunotherapy company PDS Biotechnology (PDSB) joined the Russell Microcap Index. Frank Bedu-Addo, President and CEO of PDS Biotech, commented, "Inclusion in the Russell Microcap Index underscores the pro...

FLORHAM PARK, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, was added to the Russell Micro...

Mario13/E+ via Getty Images Intellia has a “more de-risked platform” now: Jefferies Intellia Therapeutics (NTLA) and Regeneron (REGN) have climbed sharply in the pre-market after the duo marked a milestone in CRISPR gene-editing with interim results for NTLA-2001 in transthyreti...

Gainers: Geron (GERN) +48%.CAI International (CAI) +46%.Sykes Enterprises (SYKE) +30%.PDS Biotechnology (PDSB) +18%.Smith & Wesson Brands (SWBI) +17%.Biophytis (BPTS) +13%.SemiLEDs (LEDS) +10%.Clean Energy Fuels (CLNE) +10%.Luokung Technology (LKCO) +10%.Vinco Ventures (BBIG) +9%.Los...

PDS Biotechnology (PDSB) announces the closing of its previously announced underwritten public offering of 6M shares at a price of $8.50/share for gross proceeds of about $51.7M.The company highlighted that the offering was inclusive of the 794K shares that were sold pursuant to the...

FLORHAM PARK, N.J., June 17, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy company developing a pipeline of novel cancer therapies based on the Company’s proprietary Versamune ® T-...

Gainers: Clearside Biomedical (CLSD) +30%, Eloxx Pharmaceuticals (ELOX) +15%, Fusion Pharmaceuticals (FUSN) +14%, Precipio (PRPO) +14%, Ocugen (OCGN) +11%.Losers: PDS Biotechnology (PDSB) -27%, Sage Therapeutics (SAGE) -16%, Neu...

PDS Biotechnology (PDSB) slumps 27% premarket after pricing its public offering of 5,294,118 common shares at $8.50/share, for expected gross proceeds of ~$45M.Underwriters' over-allotment is an additional 794,117 shares. Net proceeds will be used for the development of clinical pip...

FLORHAM PARK, N.J., June 15, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune &#x...